Education
About Us
Working with TipRanks
Follow Us
Cartesian Therapeutics (RNAC)
NASDAQ:RNAC
RNAC Stock Chart & Stats
$7.55
-$0.34(-1.95%)
At close: 4:00 PM EST
$7.55
-$0.34(-1.95%)
Day’s Range― - ―
52-Week Range$8.46 - $26.50
Previous CloseN/A
Volume45.37K
Average Volume (3M)79.92K
Market Cap
$200.48M
Enterprise Value$127.81M
Total Cash (Recent Filing)$143.38M
Total Debt (Recent Filing)$12.60M
Price to Earnings (P/E)―
Beta2.15
Next Earnings
Mar 05, 2026EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding26,002,043
10 Day Avg. Volume83,590
30 Day Avg. Volume79,917
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)-68.21
Price to Sales (P/S)11.92
P/FCF Ratio-14.16
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue117.15
Enterprise Value/Gross Profit200.02
Enterprise Value/Ebitda-9.30
Forecast
1Y Price Target
$39.75Price Target Upside426.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentEnrollment for Cartesian's pivotal study in severe myasthenia gravis (MG) continues on schedule with readout in 2027.
Financial PerformanceTotal 2Q25 net income was 15.9M vs. a net loss estimate of $17.5M.
Safety ProfileDescartes-08 is delivered without flu/cy conditioning, which enhances its safety profile and value proposition.
Bears Say
Clinical Data RisksRisks include, but are not limited to: (2) failure to generate favorable clinical data, particularly with Descartes-08 in MG.
Standard Of Care ChallengesNon-responders to current standard of care are at high risk of organ failure and even death, with a lack of disease-modifying therapies available.
Trial DelaysRisks include, but are not limited to: (1) delays in moving candidates through trials.
Cartesian Therapeutics News
RNAC FAQ
What was Cartesian Therapeutics’s price range in the past 12 months?
Cartesian Therapeutics lowest stock price was $8.46 and its highest was $26.50 in the past 12 months.
What is Cartesian Therapeutics’s market cap?
Cartesian Therapeutics’s market cap is $200.48M.
When is Cartesian Therapeutics’s upcoming earnings report date?
Cartesian Therapeutics’s upcoming earnings report date is Mar 05, 2026 which is in 117 days.
How were Cartesian Therapeutics’s earnings last quarter?
Cartesian Therapeutics released its earnings results on Nov 06, 2025. The company reported -$1.38 earnings per share for the quarter, missing the consensus estimate of -$0.847 by -$0.533.
Is Cartesian Therapeutics overvalued?
According to Wall Street analysts Cartesian Therapeutics’s price is currently Undervalued.
Does Cartesian Therapeutics pay dividends?
Cartesian Therapeutics does not currently pay dividends.
What is Cartesian Therapeutics’s EPS estimate?
Cartesian Therapeutics’s EPS estimate is -1.01.
How many shares outstanding does Cartesian Therapeutics have?
Cartesian Therapeutics has 26,002,043 shares outstanding.
What happened to Cartesian Therapeutics’s price movement after its last earnings report?
Cartesian Therapeutics reported an EPS of -$1.38 in its last earnings report, missing expectations of -$0.847. Following the earnings report the stock price went down -1.565%.
Which hedge fund is a major shareholder of Cartesian Therapeutics?
Currently, no hedge funds are holding shares in RNAC
Cartesian Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$39.75 (426.49% Upside)
$39.75 (426.49% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 5.5%
Last 30 Days ▼ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-58.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.83%
Trailing 12-Months
Company Description
Cartesian Therapeutics
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.
RNAC Stock 12 Month Forecast
Average Price Target
$39.75
▲(426.49% Upside)
Technical Analysis
Puma Biotechnology
―
DBV Technologies SA - American
―
Voyager Therapeutics
―
Atea Pharmaceuticals
―
Vor Biopharma
―